Abstract:Objective: Large abdominal aortic aneurysms (AAAs) present a significant mortality risk. While numerous medical interventions have been proposed, no drugs have convincingly reduced AAA progression, rupture rates, or repair risk. This systematic review and meta-analysis aimed to assess the impact of re-purposed drugs or dietary supplements on slowing expansion rates, reducing the risk of rupture, or minimising the risk of repair for individuals with AAA. Methods: A systematic search was conducted in five databases. Both observational studies and randomised controlled trials were included. Unpublished data from two screening trials were incorporated. Risk of bias was assessed using the Newcastle-Ottawa scale and revised Cochrane risk of bias tool. Meta-analyses were performed for each identified drug subclass and were stratified by overall risk of bias. Results were reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: Of 7 484 screened studies, 39 met the inclusion criteria. No studies on dietary supplements were included. A total of 84 cohorts were derived from the included studies, and twelve distinct drug groups underwent meta-analyses. Two drug groups, metformin and statins, were statistically significant in slowing AAA growth. No low risk of bias studies were included for these two drug groups, and the results had very high heterogeneity (I2 > 80%). Both groups had a GRADE certainty of very low. Metformin, excluding high risk of bias studies, presented an estimated mean growth difference of AAA diameter between users and non-users of -0.73 mm/year, whilst statins had an overall estimated mean difference of -0.84 mm/year. Conclusion: This systematic review and meta-analysis suggests that metformin and statins may provide some effect in slowing AAA progression. However, no definitive evidence was found for any of the investigated drugs included in this study. Further research is needed to identify effective medical treatments for AAA progression with more robust methodology.

Current Pharmacological Management of Aortic Aneurysm

Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm

Aortic aneurysm: pathophysiology and therapeutic options

Potential Medication Treatment According to Pathological Mechanisms in Abdominal Aortic Aneurysm

Therapeutic potential of natural products and underlying targets for the treatment of aortic aneurysm

Molecular targets in aortic aneurysm for establishing novel management paradigms

Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm

Lack of an effective drug therapy for abdominal aortic aneurysm

Using Molecular Targets to Predict and Treat Aortic Aneurysms.

Innovation in pathogenesis and management of aortic aneurysm

The mechanism and therapy of aortic aneurysms

The future for the therapeutics of abdominal aortic aneurysm: engineered nanoparticles drug delivery for abdominal aortic aneurysm

Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome

Abdominal aortic aneurysm: update on pathogenesis and medical treatments

Status of diagnosis and therapy of abdominal aortic aneurysms

Endothelium as a Potential Target for Treatment of Abdominal Aortic Aneurysm

Pharmaceutical Modulation of Intracranial Aneurysm Development and Rupture

Current knowledge and contemporary management of non-A non-B aortic dissections

Exploring Drug Re-Purposing for Treatment of Abdominal Aortic Aneurysms: a Systematic Review and Meta-analysis

Animal Models, Pathogenesis, and Potential Treatment of Thoracic Aortic Aneurysm

Advances and challenges in regenerative therapies for abdominal aortic aneurysm